



IFW

PATENT

Case Docket No. ABGENIX.043A

Date: July 9, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Mulkerrin, et al.
App. No. : 10/821,626
Filed : April 9, 2004
For : ASPARAGINE DEAMINASE
CATALYTIC ANTIBODIES
Examiner : Unassigned
Group Art Unit : 1646

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 9, 2004

(Date)

Erik T. Anderson, Reg. No. 52,559


TRANSMITTAL LETTER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with ten (10) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Erik T. Anderson
Registration No. 52,559
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Mulkerrin, et al.
App. No. : 10/821,626
Filed : April 9, 2004
For : ASPARAGINE DEAMINASE
CATALYTIC ANTIBODIES
Examiner : Unassigned
Group Art Unit : 1646

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed is form PTO-1449 listing ten (10) references that are also enclosed.

This Information Disclosure Statement is being filed with an RCE or within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 7-9-04

By: 
Erik T. Anderson
Registration No. 52,559
Attorney of Record
Customer No. 20,995
(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABGENIX.043AAPPLICATION NO.
10/821,626INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Mulkerrin, et al.FILING DATE
April 9, 2004GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	4,659,567	04/21/87	Tramontano, et al.			
	2	5,236,836	08/17/93	Paul			
	3	5,439,812	08/08/95	Benkovic, et al.			
	4	5,599,538	02/04/97	Paul, et al.			
	5	5,627,052	05/06/97	Schrader			
	6	5,658,753	08/19/97	Paul, et al.			
	7	6,235,714	05/22/01	Paul, et al.			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
	8	Babcook, et al., "A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities", Proc. Natl. Acad. Sci. USA, vol. 93, pp. 7843-7848, (July 1996).					
	9	Gibbs, et al., "Antibody-catalyzed rearrangement of the peptide bond", Science, vol. 258, pp. 803-805, (October 30, 1992).					
	10	Huse, et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda", Science, vol. 246, pp. 1275-1281 (December 8, 1989).					

S:\DOCS\MMAMMA-8452.DOC/cfg/070804

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	